Skip to main content
. 2008 Mar 6;27(7):934–947. doi: 10.1038/emboj.2008.40

Figure 9.

Figure 9

Assembly of the cis-Golgi is impaired by ZFPL1 depletion or microinjection of ZFPL1 antibodies. (A) HeLa cells were treated with control (Luciferase) siRNA or siRNA targeting ZFPL1 for 72 h, incubated with 5 μg/ml BFA for 1 h at 37°C and either fixed directly or the drug washed out for an additional 2 h. Cells were labelled with antibodies to GM130 and visualized by epifluorescence microscopy. (B) SiRNA-treated cells were incubated with 5 μg/ml BFA for 1 h, and the drug was washed out for a further 2 h before double-labelling with antibodies to GM130 (green) and GalNacT2, ERGIC53 or p115 (red) and visualization by confocal microscopy. (C) HeLa cells were treated with 5 μg/ml BFA for 1 h, micro-injected in the presence of BFA with rabbit IgG (control) or affinity-purified antibodies to ZFPL1 (CD), washed to remove the drug and incubated for a further 2 h before fixation and labelling with antibodies to GM130. Injected cells are marked with an asterisk. Scale bar, 10 μm.